It’s difficult to find much comfort with Stryker’s (SYK)
valuation, but the company continues to deliver exceptional financial
results that at least help kick the valuation can a little further down
the road. MAKO continues to drive share growth from Stryker in knee
implants, while new power tools are driving strong surgical equipment
growth, and the company continues to benefit from expanding penetration
of interventional procedures for stroke patients.
I
won’t try to justify the price Stryker is trading at today. Medical
devices in general are trading well above long-term norms, but Stryker
continues to deliver exceptional financial performance across its
business units. I wouldn’t want to be caught without a chair when the
music stops, but I know better than to assume that Stryker’s high
valuation alone would prevent the shares from heading higher.
Read more here:
Stryker's Exceptional Growth Supports A Gravity-Defying Valuation
No comments:
Post a Comment